Patents Examined by Joseph F. Murphy
  • Patent number: 7078481
    Abstract: The invention provides isolated nucleic acids molecules, designated PCIP nucleic acid molecules, which encode proteins that bind potassium channels and modulate potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PCIP nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PCIP gene has been introduced or disrupted. The invention still further provides isolated PCIP proteins, fusion proteins, antigenic peptides and anti-PCIP antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: July 18, 2006
    Assignees: Wyeth, Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth Rhodes, Maria Betty, Huai-Ping Ling, Wenqian An
  • Patent number: 7074589
    Abstract: Nucleic acid molecules encoding full length PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP polypeptides, portions of such nucleic acid molecules, nucleic acid vectors containing such nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying compounds that bind such polypeptides or abrogate their interactions with natural binding partners. Methods for diagnosing abnormal conditions in an organism with PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP related molecules or compounds. PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, or SIRP polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing.
    Type: Grant
    Filed: June 17, 1997
    Date of Patent: July 11, 2006
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Axel Ullrich, Naohito Aoki, Yeong Woong Kim, Hong Yang Wang, Zhengjun Chen, Oliver Nayler, Alexei Kharitonenkov
  • Patent number: 6989435
    Abstract: Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.
    Type: Grant
    Filed: September 11, 1997
    Date of Patent: January 24, 2006
    Assignee: Cambridge University Technical Services Ltd.
    Inventors: David J. Grainger, Lauren Marie Tatalick
  • Patent number: 6955894
    Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are method for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: October 18, 2005
    Assignee: The Regents of the University of California
    Inventors: Tetsuya Gatanaga, Gale A. Granger
  • Patent number: 6930084
    Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: August 16, 2005
    Assignee: The Regents of the University of California
    Inventors: Gale A. Granger, Tetsuya Gatanaga
  • Patent number: 6911314
    Abstract: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: June 28, 2005
    Assignee: The Regents of the University of California
    Inventors: Tetsuya Gatanaga, Gale A. Granger
  • Patent number: 6893858
    Abstract: An isolated polynucleotide encoding a novel potassium channel polypeptide, KCNQ5, that is expressed primarily in brain and skeletal muscle is described. The new polypeptide has been cloned and isolated from a human brain cDNA library and is a member the KCNQ family of potassium channels. The provided human KCNQ5 nucleic acid sequence and encoded polypeptide can be employed for diagnostic, screening and therapeutic uses.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: May 17, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Steven I. Dworetzky, Chandra S. Ramanathan, Joanne T. Trojnacki, Valentin K. Gribkoff
  • Patent number: 6891028
    Abstract: The present invention provides isolated nucleic acids encoding TfR2 polypeptides, or fragments thereof, and isolated TfR2 polypeptides encoded thereby. Further provided are vectors containing the nucleic acids of the present invention, host cells transformed therewith, antisense oligonucleotides thereto and compositions containing antibodies that specifically bind to invention polypeptides. Methods of detecting TfR2 protein in a cell are also provided.
    Type: Grant
    Filed: July 22, 1999
    Date of Patent: May 10, 2005
    Assignee: Cedars-Sinai Medical Center
    Inventors: Hiroshi Kawabata, H. Phillip Koeffler
  • Patent number: 6867017
    Abstract: Disclosed is a novel ATP-binding cassette gene (ABC7), polypeptide and methods of detecting mutations therein. Further, the disclosure provides methods of detecting ABC7 associated disease and treatments thereof. In particular, the disclosure provides methods of detecting X-linked Sideroblastic Anemia and Ataxia associated with a mutation in the ABC7 polypeptide.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: March 15, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael Dean, Rando Allikmets, Amy Ann Hutchinson
  • Patent number: 6855507
    Abstract: Under the knowledge which two kinds of intracellular signal transfer mechanism of TGF-? super family receptor exist: a pathway via Smad molecule and a pathway via novel MAP kinase such as TAB1 and TAK1, and the knowledge of interaction of Smad molecule with intranuclear receptor or CBP/p300 on the transcription control by Smad molecule, a screening method and a molecular designing method for pharmaceuticals with identified site of action and higher specificity can be accomplished.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: February 15, 2005
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Shigeaki Kato, Jun Yanagisawa
  • Patent number: 6849727
    Abstract: This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.
    Type: Grant
    Filed: March 29, 2000
    Date of Patent: February 1, 2005
    Assignee: H.Lundbeck A/S
    Inventors: Christophe P. G. Gerald, Kenneth A. Jones, James A. Bonini, Beth E. Borowsky, Douglas A. Craig
  • Patent number: 6835546
    Abstract: The present invention provides a Drosophila melanogaster GPCR (DmGPCR) polypeptides and polynucleotides which identify and encode such a DmGPCR. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of homologs in other animals, and of DmGPCR agonists/antagonists, useful for the treatment of diseases in animals and for the control of insects that are injurious or harmful to plants or animals.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: December 28, 2004
    Assignee: Pharmacia & Upjohn Company
    Inventors: David E. Lowery, Valdin G. Smith, Teresa M. Kubiak, Martha J. Larsen
  • Patent number: 6833240
    Abstract: Polymorphic nucleic acid molecules encoding the very low density lipoprotein receptor are described, as well as gene products encoded by these nucleic acid molecules. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also described, along with methods of use therefor.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: December 21, 2004
    Assignees: McGill University, Complexe Hospitalier de la Sagamie
    Inventors: James C. Engert, Marie-Claude Vohl, Carl Brewer, Kenneth Morgan, Daniel Gaudet, Thomas J. Hudson
  • Patent number: 6833440
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of hElk, antibodies to hElk, methods of detecting hElk, methods of screening for voltage-gated potassium channel activators and inhibitors using biologically active hElk, and kits for screening for activators and inhibitors of voltage-gated potassium channels comprising hElk.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: December 21, 2004
    Assignee: Icagen, Incorporated
    Inventors: Timothy J. Jegla, Alan Wickenden
  • Patent number: 6824777
    Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: November 30, 2004
    Assignees: Licentia Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Arja Kaipainen, Reija Valtola, Lotta Jussila
  • Patent number: 6825324
    Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: November 30, 2004
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Will F. Baron
  • Patent number: 6818419
    Abstract: The present invention provides nucleic acids and polypeptides for IRAK-4, a novel member of the IRAK family of protein kinases. Members of the IRAK family are indispensable signal transducer for members of the IL-1R/Toll family of transmembrane receptors, including IL-1 receptors, IL-18 receptors and LPS receptors. IRAK-4 sequences from human and mouse are provided, as are methods for identifying compounds useful in the treatment or prevention of inflammatory diseases.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: November 16, 2004
    Assignee: Tularik Inc.
    Inventors: Holger Wesche, Shyun Li
  • Patent number: 6818758
    Abstract: The present invention is based on sequencing genomic DNA from human chromosome 6 and cDNAs to define the genomic structure of estrogen receptor beta genes and novel polymorphism in the estrogen receptor gene/protein. Such polymorphism can lead to a variety of disorders that are mediated/modulated by a variant estrogen receptor, such as a susceptibility to cancer, osteoporosis, cardiovascular disorder, etc. Based on this sequencing approach, the present invention provides genomic nucleotide sequences, cDNA sequences, amino acid sequences and sequence polymorphism in the ESR-beta genes, methods of detecting these sequences/polymorphism in a sample, methods of determining a risk of having or developing a disorder mediated by a variant estrogen receptor and methods of screening for compounds used to treat disorders mediated by a variant estrogen receptor.
    Type: Grant
    Filed: January 24, 2001
    Date of Patent: November 16, 2004
    Assignee: Applera Corporation
    Inventors: Francis Kalush, Michael J Cassel, Stuart Soo-In Hwang, Emily S Winn-Deen
  • Patent number: 6806352
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: October 19, 2004
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Patent number: 6806061
    Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C-C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof, and to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: October 19, 2004
    Assignees: Children's Medical Center Corporation, Millennium Pharmaceuticals, Inc., Brigham and Women's Hospital
    Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin